1,304 research outputs found
Intervista a Luciano Giaccari
No full textLuciano Giaccari ha dato un notevole contributo a partire dagli anni Settanta allo sviluppo della videoarte in Italia, costituendo un archivio a Varese per la conservazione della memoria di queste nuove tipologie artistiche. L'originalità e l'importanza di queste raccolte speciali, consiste nella sistematicità delle riprese in videotape durante i decenni degli eventi di performing-art da parte di un unico operatore rispetto al patrimonio di altri centri-video che raccolgono prodotti disomogenei di differenti provenienze ma soprattutto nella possibilità di consultazione grazie a criteri, elaborati per la classificazione degli stessi video. Molte performance di arte, musica, danza, teatro, poesia per il loro carattere "effimero" non avrebbero tramandato la memoria se Luciano Giaccari non fosse stato un testimone onnipresente. Dal circuito delle gallerie private a quello istituzionale si assiste ad un altro fenomeno: la proiezione dei video d'artista. Essa rappresenta un'altra realtà, un'altra modalità che affida la creatività a una mediazione tecnologica ed elettronica. La videoteca Giaccari trasformatasi nel 1995 in Muel di Varese (museo elettronico) include anche questa produzione, avvalendosi di un laboratorio audiovisivo ed informatico. Il processo di digitalizzazione a cui sono stati sottoposti i materiali della raccolta Giaccari ha evitato il rischio di perdita dei video e l'organizzazione della banca dati rende più facile la loro consultazione. Vengono qui affrontate problematiche inerenti i linguaggi delle nuove tendenze del contemporaneo e una breve storia recente del loro sviluppo
Long-Term Effectiveness of Once-Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real-World Study
No full textBackground: The introduction of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has provided new avenues for managing type 2 diabetes (T2D), aiming to achieve optimal glycaemic control while minimising treatment burden. We conducted a multicentre retrospective real-world study to assess the effectiveness of semaglutide once-weekly (OW) in patients previously treated with insulin. Methods: We included individuals with T2D who were on insulin (basal and/or bolus) and initiated OW semaglutide at 18 specialist care centres. We collected retrospective data on baseline clinical characteristics and updated values of HbA1c and body weight. The primary outcome was the change in HbA1c analysed using the mixed model for repeated measures. Secondary outcomes included the changes in body weight, insulin discontinuation and the change in insulin doses. Results: The study included 674 individuals. At baseline, participants were 61.7 years old, with a mean diabetes duration of 11.5 years and an HbA1c of 8.2%. During a median follow-up of 18 months, OW semaglutide initiation led to a significant reduction in HbA1c (−0.9%) and body weight (−4.3 kg), with 60% of patients achieving HbA1c < 7%. 32.8% of patients discontinued insulin therapy, 72.5% of whom achieved an HbA1c < 7%. Among patients on basal-bolus insulin, 75% completely discontinued bolus, 62% of whom achieved an HbA1c < 7%. Predictors of insulin discontinuation included shorter diabetes duration, lower baseline HbA1c, and lower insulin doses. Among patients who remained on insulin, initiation of OW semaglutide was associated with a decrease in total daily insulin requirement. Conclusion: Our study highlights OW semaglutide as a valuable addition to a T2D regimen based on insulin, offering effective glycaemic and weight control with the potential for insulin deintensification or discontinuation
Gestione aziendale e comportamenti illeciti
No full textCollana dei Quaderni della Rivista Economia, Azienda e Svilupp
Maud e la videoteca Giaccari tra anni Sessanta e Settanta
No full textOggetto dell’analisi è la figura di Maud Ceriotti Giaccari (o "CG Maud"), la quale ha saputo essere insieme artista, imprenditrice, giornalista, gallerista e collaboratrice del compagno di vita Luciano Giaccari – personalità tra le più significative e peculiari della stagione storica dell’arte video italiana. L’intento dello scritto è quello di indagare una figura poliedrica che ha saputo conciliare vita professionale e vita artistica accanto al marito, partecipando in modo attivo alla fondazione e conduzione dello Studio 970 2 (1967) prima e della Videoteca Giaccari poi (dal 1977).
Si ripercorre in particolare il lavoro artistico che GC Maud svolge tra il 1968 e il 1970 partecipando a diversi eventi artistici extraufficiali impostando una ricerca che amplia fino ai generi dell’effimero. Nel solco di questa attitudine nel 1972 firma Autobiografogramma, suo unica opera video e ultima, la quale viene qui indagata per la prima volta
Self-management in patients with type 2 diabetes: Group-based versus individual education. A systematic review with meta-analysis of randomized trails
No full textAim: Patient education is an essential component of the treatment of type 2 diabetes mellitus (T2DM). The present meta-analysis was aimed at verifying the efficacy of group-based versus individual education for self-management in patients with T2DM. Data synthesis: A Medline and Embase search up to January 1st, 2021, was performed, including Randomized Controlled Trials (RCT) with duration>6 months, enrolling patients with T2DM and comparing individual-based with group-based educational programs. The primary outcome was endpoint HbA1c; secondary endpoints were lipid profile, body weight, blood pressure, patients’ adherence/knowledge, and quality of life. The weighed difference in means (WMD) and Mantel-Haenzel Odds Ratio (MH–OR), with 95% Confidence Interval (CI), were calculated. We retrieved 14 RCT. No significant between-group difference in HbA1c (WMD -0.39[-0.89; 0.09] mmol/mol, p = 0.11) was observed. At metaregression analyses, longer trial duration, higher baseline mean age and duration of diabetes, and lower baseline HbA1c were correlated with greater efficacy of group-based programs in reducing HbA1c. When analyzed separately, trials excluding insulin-treated patients showed a significant reduction of HbA1c in favor of group education. Conclusions: In patients with T2DM, group education has similar efficacy as individual education on glucose control. Group programs are associated with an improved quality of life and patients’ knowledge. Prospero and OSF registration: ID243149
Un gis per la pianificazione degli interventi atti a mitigare il rischio idrogeologico del bacino endoreico del torrente Asso, a sud di Lecce.
No full textIl torrente Asso è un antico corso fluviale naturale che, nel passato, convogliava le sole acque della
zona a Sud di Lecce tra i comuni Nardò, Galatone, Seclì, Noha, Aradeo per condurle a Nord, in
contrada “Paduli” in agro di Nardò, dove si accumulavano su una vasta area, leggermente depressa,
e stazionavano per un lungo periodo di tempo fino a permeare nel sottosuolo molto lentamente.
Nel corso degli anni, un susseguirsi di interventi antropici hanno ridisegnato ed ampliato il reticolo
idrografico, spesso con angoli a 90 gradi e per approvvigionare le aree secche e per bonificare le aree
perennemente allagate, poste a Nord del centro abitato di Nardò talchè, il vecchio torrente Asso,
allungato, ridimensionato e rimodellato, ha dovuto trasportare, fino ad oggi, portate di gran lunga
superiori a quelle che la natura originariamente gli aveva destinato.
Le conseguenze sono state catastrofiche: esondazioni ed alluvioni hanno interessato ed interessano
ancora oggi, in occasione di piogge di elevata intensità, anche di breve durata, vaste aree urbane ed
agricole dei centri urbani di Nardò, Galatone, Seclì, Aradeo, Neviano, Collepasso, Cutrofiano,
Parabita, Matino e Casarano, in provincia di Lecce.
Con l’ausilio di un GIS, appositamente predisposto, vengono illustrati i risultati dello studio
approntato per la mitigazione del rischio idrogeologico
Sodium-glucose co-transporter inhibitors: Medications that mimic fasting for cardiovascular prevention
No full textRecent evidence that some diabetes drugs can prevent cardiovascular disease (CVD) has profoundly modified the treatment approach to type 2 diabetes mellitus. Sodium-glucose co-transporter-2 (SGLT2) inhibitors and almost all glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown, beyond their effect on glucose control, to lead to a significant decrease in the cardiovascular burden of diabetes. Although these results are well known, the mechanisms of action by which they prevent cardiovascular events are still poorly understood. Both GLP-1RAs and SGLT2 inhibitors promote weight loss, although through different mechanisms. SGLT2 inhibitors promote glycosuria, leading to significant caloric deficit and weight loss. Similarly, GLP-1RAs, probably through an anorexic effect on certain brain areas, inhibit calorie intake, with ensuing weight loss. Although it features less prominently in current treatment pathways, pioglitazone has also demonstrated cardiovascular benefits. Pioglitazone profoundly modifies several mechanisms and risk factors responsible for CVD; however, these mechanisms certainly do not include weight loss. Obesity, and consequent insulin resistance, are well known risk factors for CVD, and it would appear logical to attribute the positive cardiovascular effects of these two classes of drugs to weight loss. The direct metabolic effects of these two classes, however, are profoundly different. The present review proposes a unifying hypothesis to explain the reduction in CVD through three different mechanisms of curbing free fatty acid excess, all leading to the common mechanism of cellular caloric restriction. If this hypothesis is correct, the excellent results obtained with SGLT2 inhibitors could be attributed to their close simulation of fasting
SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice
No full textSodium-glucose cotransporter-2 inhibitors (SGLT-2i), initially studied and approved for the treatment of diabetes, are now becoming a promising class of agents to treat heart failure (HF) and chronic kidney disease (CKD), even in patients without diabetes. While the potential benefits in several diseases (usually treated by different medical specialties) is amplifying the interest in these drugs, their use in frail patients with multiple pathologies and on polypharmacy can be complex, requiring a composite multidisciplinary approach. Following a brief overview of the evidence supporting the benefits of SGLT-2i in patients with HF or CKD, we herein provide guidance for prescribing SGLT-2i in daily practice using a multidisciplinary approach. A shared treatment algorithm is presented for initiating an SGLT-2i in patients already being treated for diabetes and HF. Tools to prevent hypoglycemia, blood pressure drop, genital infections, euglycemic diabetic ketoacidosis and eGFR dip are also provided. It is hoped that this practical, multidisciplinary guidance for initiating SGLT-2i in patients with HF and/or CKD, whatever therapy they are currently on, can help to offer SGLT-2i to the largest population of patients possible to provide the most therapeutic benefit
- …
